Altered Methylation Pattern of the SRD5A2 Gene in the Cerebrospinal Fluid of Post-Finasteride Patients: A Pilot Study

    July 2019 in “ Endocrine connections
    Roberto Cosimo Melcangi, Livio Casarini, Marco Marino, Daniele Santi, Samantha Sperduti, Silvia Giatti, Silvia Diviccaro, M.G. Grimoldi, Donatella Caruso, Guido Cavaletti, Manuela Simoni
    New to Finasteride? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that post-finasteride syndrome patients showed a tissue-specific methylation pattern of the SRD5A2 promoter in cerebrospinal fluid, potentially affecting neuroactive steroid levels and related behavioral symptoms.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This pilot study investigated the methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients. The study found that the methylation pattern of the SRD5A2 gene was altered in post-finasteride patients compared to controls, suggesting that epigenetic modifications may play a role in the persistent adverse effects of finasteride. However, further studies with larger sample sizes are needed to confirm these findings.
    Discuss this study in the Community →

    Research cited in this study

    26 / 26 results